We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ValenzaBio

News List

ValenzaBio, ProBioGen Enter Cell Line Pact contractpharma
July 29, 2021
ProBioGen and ValenzaBio have initiated a cell line development project involving the application of ProBioGen's GlymaxX technology.
ValenzaBio Partners with ProBioGen to Maximize Cell Line Productivity and Licenses GlymaxX® b3cnewswire
July 28, 2021
ProBioGen and ValenzaBio today jointly announced the initiation of a cell line development project involving the application of ProBioGen's proprietary GlymaxX technology.
ValenzaBio Advances Pipeline of Antibody Therapeutics Toward Clinical Development for Autoimmune and Inflammatory Diseases americanpharmaceuticalreview
April 12, 2021
ValenzaBio, Inc., a biopharmaceutical company developing monoclonal antibody therapeutics for autoimmune and inflammatory indications, announced the completion of a $70 million Series A financing from premier investors Fidelity Management & Research ...